ERNA · Ernexa Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $6.25M |
| P/E | — |
| Float | 680.0K |
| Beta | 2.69 |
| Volatility | 67.2% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Micro cap |
| Macro sensitivity | Very High |
| Clavix score | 22 |
| Price | 3.90 |
| Change | +1.83% |
| Prev Close | 3.83 |
| Open | 3.79 |
| Day Low | 3.79 |
| Day High | 3.88 |
| Avg Vol | 0 |
| Avg $ Vol | $283.9K |
| 52W High | 71.50 |
| 52W Low | 3.18 |
| 52W Pos | 1.0% |
| From High | −94.55% |
| From Low | +22.53% |
| Max DD 1Y | −93.02% |
| Spread | 0.10% |
| Liquidity | Thin |
| SMA 20 | −10.92% |
| SMA 50 | −13.42% |
| SMA 200 | −66.73% |
| RSI (14) | 38.2 |
| Vol 30D | 59.6% |
| Vol 90D | 154.3% |
| 1Y Range | 3–72 |
| Daily bars | 516 |
| Perf Week | −8.04% |
| Perf Month | −13.54% |
| Perf Quarter | −38.23% |
| Perf Half Y | −43.26% |
| Perf Year | −87.02% |
| Perf YTD | −86.55% |
| Prev Day | +1.83% |
| Clavix | F |
| Debt / Eq | 0.31 |
| Curr Ratio | 1.01 |
| Int Cover | -5.5× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 34 / 35 |
Clavix risk grade
regraded every trading dayERNA grades F, 22 of 100. Steadiest on News Sentiment (58), most exposed on Price Stability (3, weak). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 34 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ERNA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.69 | 0.51 |
| Volatilityannualized | 67.2% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −93.0% | — |
| Typical daily movemedian absolute daily change | 4.17% | — |
| Days beyond ±3%of the last 252 sessions | 16465% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ERNA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.69 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ERNA | |
|---|---|
| 1 week | −8.0% |
| 1 month | −13.5% |
| Year to date | −86.6% |
| 1 year | −87.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ERNA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 24since 6 May |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 2 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ERNA | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openErnexa Therapeutics announced the appointment of Dr. Robert J. Spiegel, a former Chief Medical Officer at Schering-Plough and PTC Therapeutics, to its Board of Directors as the company advances its lead cell therapy candidate ERNA-101 toward clinical development.
Ernexa Therapeutics appointed Robert J. Spiegel, M.D. to a leadership role. He previously served as Chief Medical Officer at Schering-Plough and PTC Therapeutics, with experience in clinical development, regulatory affairs, and oncology.
Ernexa Therapeutics (ERNA) appointed Dr. Robert J. Spiegel to its Board of Directors on September 14, 2026, effective immediately, upon the recommendation of its Nominating and Corporate Governance Committee. The filing is a standard regulatory disclosure confirming no undisclosed agreements or family ties between Spiegel and other company insiders.
Ernexa Therapeutics reported that its ERNA-201 program showed promising disease-modifying results in a standard preclinical arthritis test, adding evidence that its engineered stem cell platform works beyond cancer. The company said it is focusing near-term resources on ERNA-101 as it prepares to begin first-in-human clinical trials in oncology.
Ernexa Therapeutics reported that ERNA-201, a treatment built from its lab-made stem cell platform (iMSCs, meaning induced mesenchymal stem cells), showed disease-modifying results in a standard arthritis animal model. The company also said it is moving its lead cancer drug ERNA-101 closer to first-in-human trials while sharpening its focus on oncology.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| VIVS | VivoSim Labs Inc | D- | $4.31M | — | 1.59 | Compare |
| QTTB | Q32 Bio Inc | F | $313.8M | 10.52 | 0.51 | Compare |
| CELC | Celcuity Inc | C | $3.94B | — | 0.14 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $4.64B | — | 0.87 | Compare |
| ERAS | Erasca Inc | C | $5.17B | — | 0.71 | Compare |
| PTCT | PTC Therapeutics Inc | B | $5.46B | 7.99 | 0.50 | Compare |
| CGON | CG Oncology Inc | B- | $6.61B | — | 0.21 | Compare |
| IONS | Ionis Pharmaceuticals Inc | B- | $7.39B | — | 0.41 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.